<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536211</url>
  </required_header>
  <id_info>
    <org_study_id>1095378</org_study_id>
    <nct_id>NCT00536211</nct_id>
  </id_info>
  <brief_title>Physical Inactivity and Insulin Resistance in Skeletal Muscle.</brief_title>
  <official_title>Physical Inactivity and Insulin Resistance in Skeletal Muscle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how a decline in physical activity acutely leads to
      a decrease in insulin sensitivity in skeletal muscle. The hypothesis is that the loss of
      insulin sensitivity following physical inactivity is caused by a rapid reduction in skeletal
      muscle mitochondrial oxidative capacity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this project we will study two diverse groups of subjects. Group 1 will be subjects who
      are sedentary, insulin resistant, and have the Metabolic Syndrome. These subjects will be
      tested for insulin sensitivity at the whole body level, and for key changes in skeletal
      muscle metabolism at baseline, following 12 weeks of exercise training, and during an acute
      (1-3 days) period of time following the cessation of exercise training. The design allows us
      to study the effects of exercise on improving insulin sensitivity and make direct comparisons
      to a period when insulin sensitivity quickly decreases because of the removal of exercise
      training. Metformin is a drug commonly prescribed to control insulin resistance and type 2
      diabetes. Metformin is thought to have exercise like effects on muscle metabolism and is
      known to activate a molecule that is de-activated during inactivity. Thus, half of the
      Metabolic Syndrome subjects will cease exercise training with no treatment while another half
      will quite exercise training while taking the drug Metformin.

      Group 2 subjects will be highly trained endurance athletes. Endurance athletes display high
      levels of insulin sensitivity that can drop in the hours and days following the cessation of
      exercise. Thus we will take the same measurements in endurance athletes at baseline during
      their normal training regimen and in the acute (1-3 days) period following the cessation of
      exercise training. Again, half of the subjects will be take Metformin during the cessation of
      exercise in the same fashion as done in group 1.

      Studies in both groups seek to determine the event(s) which cause insulin resistance in
      skeletal muscle following a decrease in physical activity levels. Comparisons between
      healthy, active individuals and sedentary Metabolic Syndrome subjects may provide additional
      information about the underlying events that cause insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    protocol not approved by VA R&amp;D
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity; following 12 weeks of exercise training and 1 and 3 days of detraining and + or - Metformin.</measure>
    <time_frame>12 weeks and 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PGC-1 alpha transcription and mitochondrial fatty acid oxidation and enzyme activity in skeletal muscle; following 12 weeks of exercise training and 1, 2, and 3 days of detraining and + or - Metformin.</measure>
    <time_frame>12 weeks and 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral tablet, 1000 mg daily for 17 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Selection of inclusion for Metabolic Syndrome Subjects :

        Sedentary metabolic syndrome subjects will be 20-55 y of age, overweight to Class I or II
        obese (BMI 25-39 kg/m2) men and women, who have a fasting glucose of 100 to 125 mg/dl, and
        at least 2 of 4 other characteristics of the metabolic syndrome which are the following:
        waist circumference greater than 102 cm in men and 88 cm in women, serum triglyceride
        concentration greater than 150 mg/dl, HDL-C concentration greater than 40 mg/dl in men and
        50 mg/dl in women, and blood pressure greater than 130/85 mmHG.

        Selection for inclusion for Endurance Athlete Subjects:

        Subjects who report training (running and/or biking) greater than 30 min a day, 4 days a
        week for at least 1 year will be included. Final inclusion criteria will be a VO2max of
        greater than 55 ml/kg/min.

        To take part in the study, Women must currently be taking birth control or be
        postmenopausal.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if they have or are:

        Diagnosed cardiovascular disease or diabetes or disease symptoms that could alter their
        ability to perform exercise, fasting blood glucose of greater than 126 mg/dl, smokers,
        taking any medications or supplements (e.g., statins, fibrates, metformin,
        thiazolidinediones, anti-hypertensives (ACE-inhibitors and angiotensin blockers) which
        could affect blood lipids or insulin sensitivity.

        Women who are pregnant or plan to become pregnant during the duration of the study For the
        Metabolic Syndrome subjects only individuals exercising regularly (more than one 30 min
        session per week) or have a physically active lifestyle (&gt;8,000 daily steps as measured by
        a pedometer) will be excluded.

        Individuals with an orthopedic limitations for walking. Allergies to drugs used in the
        study. Past or current liver and/or kidney problems of any nature.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Thyfault, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harry S. Truman Memorial Veterans' Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000 Jul;106(2):171-6. Review.</citation>
    <PMID>10903330</PMID>
  </reference>
  <reference>
    <citation>Haapanen N, Miilunpalo S, Pasanen M, Oja P, Vuori I. Agreement between questionnaire data and medical records of chronic diseases in middle-aged and elderly Finnish men and women. Am J Epidemiol. 1997 Apr 15;145(8):762-9.</citation>
    <PMID>9126003</PMID>
  </reference>
  <reference>
    <citation>Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, Dohm GL, Yan Z, Newgard CB, Muoio DM. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem. 2005 Sep 30;280(39):33588-98. Epub 2005 Aug 3.</citation>
    <PMID>16079133</PMID>
  </reference>
  <reference>
    <citation>Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, Meier CA, Bell DR, Kralli A, Giacobino JP, DÃ©riaz O. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 2003 Dec;52(12):2874-81.</citation>
    <PMID>14633846</PMID>
  </reference>
  <reference>
    <citation>Suwa M, Egashira T, Nakano H, Sasaki H, Kumagai S. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol (1985). 2006 Dec;101(6):1685-92. Epub 2006 Aug 10.</citation>
    <PMID>16902066</PMID>
  </reference>
  <reference>
    <citation>Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC. Diabetes mellitus and its vascular complications in Japanese migrants on the Island of Hawaii. Diabetes Care. 1979 Mar-Apr;2(2):161-70.</citation>
    <PMID>520120</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <name_title>John Thyfault</name_title>
    <organization>University of Missouri-Columbia</organization>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Physical Activity</keyword>
  <keyword>Metformin</keyword>
  <keyword>Hyperinsulinemic-Euglycemic Clamp</keyword>
  <keyword>Muscle Biopsy</keyword>
  <keyword>Fatty Acid Oxidation</keyword>
  <keyword>Peroxisome proliferator-activated receptor gamma</keyword>
  <keyword>Detraining</keyword>
  <keyword>Inactivity</keyword>
  <keyword>Skeletal muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

